adenine and dolutegravir

adenine has been researched along with dolutegravir in 36 studies

Research

Studies (36)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	18 (50.00)	24.3611
2020's	18 (50.00)	2.80

Authors

Authors	Studies
Fang, J; Jadhav, PR	1
Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F	1
Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY	1
Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S	1
Doherty, M; Ford, NP; Hill, AM; Khoo, SH; Pozniak, AL; Vitoria, M	1
Jones, R; Levy, JB; Milburn, J	1
Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A	1
Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K	1
Boffito, M; Flexner, CW; Maartens, G	1
Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D	1
Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K	1
Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G	1
Castagna, A; Lazzarin, A; Spagnuolo, V	1
Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y	1
Barber, TJ	1
Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X	1
Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A	1
Saag, MS	1
Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T	1
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B	1
Hill, A; Venter, WDF	1
Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D	1
Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H	1
Acosta, RK; Andreatta, K; Collins, S; Liu, H; Martin, H; Martin, R; Parvangada, A; White, KL; Willkom, M	1
Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Lalla-Edward, S; Maartens, G; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A	1
Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L	1
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B	1
Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY	1
Bendala-Estrada, AD; Bernardino, JI; Busca, C; Cadiñanos, J; Delgado-Hierro, A; Diaz-Almiron, M; Martin-Carbonero, L; Mican, R; Montejano, R; Montes, ML; Valencia, E	1
Alcalá, JC; Castro, A; Grau, S; Miró, JM; Olalla, J; Rubio-Rodríguez, D; Rubio-Terrés, C	1
Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF	1
Lunn, G	1
Abalat-Torrres, A; Arrieta-Aldea, I; Cañas-Ruano, E; Canepa, C; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Knobel, P; Marcos, A; Villar-García, J	1
Abbasian, L; Alavian, G; Alinaghi, SAS; Ashtiani, MF; Hasannezhad, M; Khalili, H; Manshadi, SAD	1
Espinosa, A; Horta, AM; Lázaro, A; Mendoza, I; Sánchez, L; Torralba, M	1
Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B	1

Reviews

5 review(s) available for adenine and dolutegravir

Article	Year
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. PloS one, 2014, Volume: 9, Issue:9 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load	2014
Renal effects of novel antiretroviral drugs. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 03-01, Volume: 32, Issue:3 Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir	2017
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. Current opinion in HIV and AIDS, 2017, Volume: 12, Issue:4 Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Rifampin; Tenofovir	2017
Bictegravir. Current opinion in HIV and AIDS, 2018, Volume: 13, Issue:4 Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Tenofovir	2018
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature. Expert review of anti-infective therapy, 2023, Volume: 21, Issue:1 Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans	2023

Trials

16 trial(s) available for adenine and dolutegravir

Article	Year
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework. Journal of pharmacokinetics and pharmacodynamics, 2012, Volume: 39, Issue:4 Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles	2012
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. The Lancet. Infectious diseases, 2013, Volume: 13, Issue:11 Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir	2013
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. The lancet. HIV, 2017, Volume: 4, Issue:4 Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult	2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107 Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult	2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107 Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult	2017
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The lancet. HIV, 2019, Volume: 6, Issue:6 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load	2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer The lancet. HIV, 2019, Volume: 6, Issue:6 Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome	2019
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. The New England journal of medicine, 2019, 08-29, Volume: 381, Issue:9 Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxazines; Phosphorous Acids; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Prodrugs; Pyridones; RNA, Viral; Uracil; Viral Load; Young Adult	2019
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 11-05, Volume: 71, Issue:8 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load	2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials The lancet. HIV, 2020, Volume: 7, Issue:6 Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult	2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. Journal of acquired immune deficiency syndromes (1999), 2020, 11-01, Volume: 85, Issue:3 Topics: Adenine; Amides; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Logistic Models; Multivariate Analysis; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir	2020
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n The lancet. HIV, 2020, Volume: 7, Issue:10 Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Weight; Cyclopropanes; Duration of Therapy; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load; Young Adult	2020
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 Lancet (London, England), 2021, 04-03, Volume: 397, Issue:10281 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridones; Tenofovir; Ultrasonography, Prenatal	2021
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-29, Volume: 75, Issue:6 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir	2022
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 04-17, Volume: 76, Issue:8 Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir	2023
Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2023, Volume: 31, Issue:2 Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Pilot Projects; RNA; Tenofovir; Treatment Outcome	2023

Other Studies

15 other study(ies) available for adenine and dolutegravir

Article	Year
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS (London, England), 2015, Jan-14, Volume: 29, Issue:2 Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load	2015
Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know? Journal of the International AIDS Society, 2016, Volume: 19, Issue:1 Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Phosphorous Acids; Piperazines; Public Health; Pyridones; Ritonavir	2016
Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infectious diseases (London, England), 2017, Volume: 49, Issue:1 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir	2017
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. Journal of acquired immune deficiency syndromes (1999), 2018, 01-01, Volume: 77, Issue:1 Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome	2018
Bictegravir and dolutegravir: head to head at 96 weeks. The lancet. HIV, 2019, Volume: 6, Issue:6 Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir	2019
HIV 101: fundamentals of antiretroviral therapy. Topics in antiviral medicine, 2019, Volume: 27, Issue:3 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load	2019
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:2 Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome	2020
Weighing considerations with newer antiretrovirals. The lancet. HIV, 2020, Volume: 7, Issue:6 Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir	2020
Cases of coronavirus disease-2019 in HIV-infected transgender women. AIDS (London, England), 2020, 07-15, Volume: 34, Issue:9 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons	2020
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. International journal of antimicrobial agents, 2022, Volume: 60, Issue:3 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia	2022
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study. HIV medicine, 2023, Volume: 24, Issue:5 Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Oxazines; Retrospective Studies	2023
Preliminary Evaluation of Stability Data for Dolutegravir-Containing Triple Active Formulations Intended for PEPFAR. Degradation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide as the Limiting Factor. Journal of pharmaceutical sciences, 2023, Volume: 112, Issue:6 Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Hygroscopic Agents; Tablets; Tenofovir	2023
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study. HIV research & clinical practice, 2023, 07-20, Volume: 24, Issue:1 Topics: Adenine; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Retrospective Studies; Treatment Outcome	2023
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults. PloS one, 2023, Volume: 18, Issue:9 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones	2023
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting. The Journal of antimicrobial chemotherapy, 2023, Dec-01, Volume: 78, Issue:12 Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir	2023